Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia, results from the EPIVAC cohort study

  • Vila Córcoles, Ángel|||0000-0002-1644-0188
  • Ochoa-Gondar, Olga
  • De Diego-Cabanes, Cinta|||0000-0001-7801-067X
  • Satue, Eva
  • Aragón, María|||0000-0002-5990-6953
  • Vila-Rovira, Angel
  • Gómez-Bertomeu, Frederic
  • Magarolas, Ramon
  • Figuerola-Massana, Enric
  • Raga, Xavier
  • Pérez Moreno, Mar Olga|||0000-0002-4216-4965
  • Ballester, Frederic
Benefits using the 13-valent pneumococcal conjugate vaccine (PCV13) in adults are controversial. This study investigated clinical effectiveness of PCV13 vaccination in preventing hospitalisation from pneumonia among middle-aged and older adults. Population-based cohort study involving 2,025,730 individuals ≥50 years in Catalonia, Spain, who were prospectively followed from 01/01/2015 to 31/12/2015. Primary outcomes were hospitalisation for pneumococcal or all-cause pneumonia and death from any cause. Cox regression models were used to evaluate the association between PCV13 vaccination and the risk of each outcome, adjusting for age, sex and major comorbidities/underlying risk conditions. Cohort members were observed for a total of 1,990,701 person-years, of which 6912 person-years were PCV13 vaccinated. Overall, crude incidence rates (per 100,000 person-years) were 82.8 (95% confidence interval [CI]: 77.7-88.1) for pneumococcal pneumonia, 637.9 (95% CI: 599.0-678.7) for all-cause pneumonia and 2367.2 (95% CI: 2222.8-2518.7) for all-cause death. After multivariable adjustments we found that the PCV13 vaccination did not alter significantly the risk of pneumococcal pneumonia (multivariable-adjusted hazard ratio [mHR]: 1.17; 95% CI: 0.75-1.83; p = 0.493) and all-cause death (mHR: 1.07; 95% CI: 0.97-1.18; p = 0.190), although it remained significantly associated with an increased risk of all-cause pneumonia (mHR: 1.69; 95% CI: 1.48-1.94; p < 0.001). In stratified analyses focused on middle-aged or elderly persons and immunocompromised or immunocompetent subjects, PCV13 vaccination did not appear effective either. Our data does not support clinical benefits of PCV13 vaccination against pneumonia among adults in Catalonia. It must be closely monitored in future studies involving more vaccinated person-time at-observation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Vacunación antineumocócica en adultos de Cataluña, coberturas y grado de adecuación a distintas guías de recomendaciones. Antipneumococcal vaccination in Catalonian adults: Vaccine coverages and adequacy to distinct guideline recommendations

  • Ochoa-Gondar, Olga
  • Vila Córcoles, Ángel|||0000-0002-1644-0188
  • De Diego-Cabanes, Cinta|||0000-0001-7801-067X
  • Satué, Eva
  • Vila-Rovira, Angel
  • Aragón, María|||0000-0002-5990-6953
Objetivos: Conocer las coberturas de vacunación antineumocócica en la población adulta de Cataluñ y analizar el grado de adecuación del estado vacunal según 3 guías distintas de recomendaciones actualmente vigentes. Diseño:Estudio transversal de base poblacional. Ámbito: Atención Primaria de Salud, Comunidad Autónoma de Cataluña. Participantes: Un total de 2.033.465 personas ≥50 años, asignadas al Institut Català de la Salut. Mediciones principales: Se revisó la recepción o no de vacuna antineumocócica polisacárida tricosavalente(VNP23) y/o conjugada tridecavalente(VNC13) a 1/01/2015. Se valoró el grado de adecuación del uso de ambas vacunas según 3 guías distintas de recomendaciones: Ministerio de Sanidad (coincidente con el Departament de Salut de Cataluña), Sociedad Española de Medicina Familiar y Comunitaria (semFYC) y Centers for Disease Control and Prevention (CDC). Resultados: Un total de 789.098 (38,8%) de personas habían recibido la VNP23 y 5.031 (0,2%) la VNC13. La cobertura de VNP23 aumentó significativamente con la edad (4,8% en 50-59años, 35,5% en 60-69 años, 71,9% en 70-79 años y 79,5% en ≥80 años; p<0,001), mientras que la cobertura de VNC13 fue muy baja en todos los grupos etarios. De acuerdo con las 3 guías analizadas, un 46,1% de los sujetos estudiados estaban adecuadamente vacunados según las recomendaciones del Ministerio de Sanidad, un 19,3% según la semFYC y un 4,6% según los CDC., Objectives: To know antipneumococcal vaccination coverages among Catalonian adults and evaluate the adequacy of vaccine use according to 3 distinct current vaccination guidelines. Design: Population-based cross-sectional study. Setting: Primary Health Care. Catalonia, Spain. Participants: A total of 2,033,465 individuals ≥ 50 years-old registered in the Catalonian Health Institute. Main measurements: Vaccination status for the 23-valent pneumococcal polysaccharide vaccine (PPV23) and/or the 13-valent pneumococcal conjugate vaccine (PCV13) was revised at 1/01/2015. Adequacy of vaccination status was determined according to 3 distinct vaccination recommendation guidelines: Spanish Ministry of Health (basically coinciding with Catalonian Health Institute's recommendations), Spanish Society of Family Physicians (semFYC) and Centers for Disease Control and Prevention (CDC). Results: Overall, 789,098 (38.8%) persons had received PPV23 and 5,031 (0.2%) had received PCV13. PPV23 coverage largely increased with increasing age (4.8% in 50-59 years, 35.5% in 60-69 years, 71.9% in 70-79 years and 79.5% in ≥ 80 years; P <.001), whereas PCV13 coverage was very small in all age groups. Considering the 3 analysed vaccine guidelines a 46.1% of the overall study population were adequacy vaccinated according to Spanish Ministry's recommendations, 19.3% according to semFYC's recommendations and 4.6% according to CDC's recommendations. Conclusion: PPV23 coverage among Catalonian adults may be considered as intermediate, but PCV13 coverage is very small. The institutional recommendations (Spanish Ministry) are more followed than corporative (semFYC) or less local (CDC) recommendations in clinical practice.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Prevalence of high, medium and low-risk medical conditions for pneumococcal vaccination in Catalonian middle-aged and older adults, a population-based study

  • Ochoa-Gondar, Olga
  • Hospital, Imma
  • Vila Córcoles, Ángel|||0000-0002-1644-0188
  • Aragón, María|||0000-0002-5990-6953
  • Jariod, M.
  • De Diego-Cabanes, Cinta|||0000-0001-7801-067X
  • Satue, E.
Updated population-based data on the frequency and distribution of risk factors for pneumococcal disease is scarce. This study investigated the prevalence of distinct comorbidities and underlying risk conditions related to an increasing risk of pneumococcal disease among Catalonian middle-aged and older adults. Cross-sectional population-based study including 2,033,465 individuals aged 50 years or older registered at 01/01/2015 in the Catalonian Health Institute (Catalonia, Spain). The clinical research database of the Information System for the Development of Research in Primary Care (SIDIAP database) was used to identify high-risk (asplenia and/or immunocompromising conditions) and other increased-risk conditions (chronic pulmonary, cardiac or liver disease, diabetes mellitus, alcoholism and/or smoking) among study subjects. Globally, 980,310 (48.2%) of the 2,033,465 study population had at least one risk condition of suffering pneumococcal disease (55.4% in men vs 42.0% in women, p < 0.001; 41.7% in people 50-64 years vs 54.7% in persons 65 years or older, p < 0.001). An amount of 176,600 individuals (8.7%) had high-risk conditions (basically immunocompromising conditions). On the other hand, 803,710 persons (39.5%) had one or more other risk conditions. In fact, 212,255 (10.4%) had chronic pulmonary diseases, 248,377 (12.2%) cardiac disease, 41,734 (2.1%) liver disease, 341,535 (16.8%) diabetes mellitus, 58,781 (2.9%) alcoholism and 317,558 (15.6%) were smokers. In our setting, approximately 50 % of overall persons 50 years or older may be considered at-risk population for pneumococcal disease (almost 10 % have high-risk conditions and 40 % have other risk conditions).